Heparina Galenica

Heparina Galenica is a medicinal product that contains the anticoagulant heparin as its active ingredient. It is supplied in a sterile injectable form intended for intravenous administration. The preparation conforms to European Union pharmaceutical standards and is available only by prescription. Heparina Galenica is used under medical supervision to provide anticoagulation in various clinical settings where blood clot prevention is required in hospital environments and intensive care units.

Heparina Galenica is indicated for several anticoagulation purposes in adult patients.

- Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or prolonged immobilization. - Treatment of acute pulmonary embolism to reduce clot burden. - Anticoagulation during cardiac surgery, including cardiopulmonary bypass. - Prevention of clot formation in extracorporeal circuits such as dialysis or ECMO. - Management of other thromboembolic conditions as determined by a physician. - Bridging anticoagulation therapy when transitioning between oral anticoagulants.

Adverse reactions to Heparina Galenica may vary in frequency and severity.

Common: - Minor bleeding at the injection site. - Small bruising or hematoma formation. - Nausea or mild gastrointestinal discomfort. - Transient elevation of liver enzymes. - Hypotension due to rapid IV administration. - Localized pain or irritation at the infusion site.

Serious: - Major hemorrhage requiring medical intervention. - Heparin-induced thrombocytopenia (HIT). - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous spinal or epidural hematoma. - Osteoporosis with long‑term use. - Severe thrombocytopenia leading to bleeding complications.

Before initiating Heparina Galenica, clinicians should evaluate several safety considerations to minimize risk.

- Assess baseline coagulation parameters (aPTT, platelet count) and renal function. - Review patient history for prior heparin exposure or heparin‑induced thrombocytopenia. - Adjust dose in patients with active bleeding or high bleeding risk. - Use caution in pregnant or breastfeeding women, as safety data are limited. - Monitor for signs of bleeding throughout therapy. - Avoid concurrent use with other anticoagulants unless specifically ordered. - Consider age‑related dosing adjustments in elderly patients.

Heparina Galenica can interact with other medications, affecting anticoagulant effect or bleeding risk.

Avoid: - Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) unless directed. - Combination with systemic thrombolytic agents (e.g., alteplase).

Use with caution: - Concomitant antiplatelet drugs such as aspirin or clopidogrel. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding. - Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulation. - High‑dose corticosteroids that may affect platelet function.